• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

by MM360 Staff | May 14, 2025 | Uncategorized

Source: CureToday articles The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression. Read More

FDA Grants Accelerated Approval to Telisotuzumab vedotin-tllv for NSCLC

by MM360 Staff | May 14, 2025 | Myeloma News

Source: Pharmacy Times articles Emrelis is a groundbreaking treatment for advanced non-small cell lung cancer, targeting high c-Met protein overexpression. Read More

Survivors of Breast Cancer May Still Struggle with Fear of Recurrence

by MM360 Staff | May 14, 2025 | Uncategorized

Source: CureToday articles Even after many cancer-free years, the fear of recurrence still lingers, and many long-term survivors struggle to keep those thoughts at bay. Read More

FDA Approves Welireg for Pheochromocytoma and Paraganglioma

by MM360 Staff | May 14, 2025 | Uncategorized

Source: CureToday articles The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma. Read More

FDA Approves Belzutifan for Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma

by MM360 Staff | May 14, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA approves belzutifan, the first oral treatment for pheochromocytoma and paraganglioma, offering a new treatment pathway for patients with these rare tumors. Read More
« Older Entries
Next Entries »

Recent Content

  • CVS Health Announces It Will Drop Zepbound and Prioritize Coverage of Wegovy
  • Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
  • Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma
  • Zepbound Shows Superior Weight Loss Compared to Wegovy in SURMOUNT-5 Trial
  • New OTC Option Offers Patients Itch Relief During Summer Activities
  • FDA Approves Emrelis in Previously Treated, Advanced NSCLC
  • FDA Grants Accelerated Approval to Telisotuzumab vedotin-tllv for NSCLC
  • Survivors of Breast Cancer May Still Struggle with Fear of Recurrence
  • FDA Approves Welireg for Pheochromocytoma and Paraganglioma
  • FDA Approves Belzutifan for Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT